Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed: single-agent and combination phase I study overview.

Michael J Boyer1, Laurent P Rivory, Stephen J Clarke

  • 1Department of Medical Oncology, Sydney Cancer Centre, Camperdown, NSW, Australia.

Seminars in Oncology
|February 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience.

Endocrine oncology (Bristol, England)·2026
Same author

Two Decades of Multimodal Management of Colorectal Liver Metastases With Long-Term Outcomes.

ANZ journal of surgery·2026
Same author

Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Real-World Outcomes of Pembrolizumab Monotherapy in Metastatic Non-Small Cell Lung Cancer by Age and Sex: A National Population-Based Study in Australia.

Clinical pharmacology and therapeutics·2026
Same author

A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions - a retrospective cohort review.

Cancer treatment and research communications·2025
Same author

[<sup>18</sup>F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Pemetrexed, a novel antifolate, shows anticancer activity by inhibiting multiple enzymes. Phase II trials established a recommended dose of 500 mg/m(2) every 21 days, with neutropenia and thrombocytopenia as dose-limiting toxicities.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pemetrexed is a novel antifolate drug targeting multiple enzymes.
  • Anticancer activity is explored through various administration schedules and combinations.

Purpose of the Study:

  • Evaluate pemetrexed's efficacy and safety in clinical trials.
  • Determine optimal dosing and administration schedules for pemetrexed therapy.

Main Methods:

  • Phase I and II clinical trials were conducted.
  • Pemetrexed was administered intravenously every 21 days.
  • Combinations with other chemotherapeutic agents were explored.

Main Results:

  • The recommended Phase II dose was established at 500 mg/m(2) every 21 days.

Related Experiment Videos

  • Dose-limiting toxicities included neutropenia and thrombocytopenia.
  • Encouraging anticancer activity was observed in combination studies.

    • Conclusions:

    • Pemetrexed demonstrates significant anticancer potential.
    • Careful dose management is crucial due to potential toxicities.
    • Combination therapies warrant further investigation for enhanced efficacy.